Verastem (VSTM) Profit After Tax Growth (1y) (2012 - 2026)

Verastem (VSTM) Profit After Tax Growth (1y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 0.26%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -107.76%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 101.22%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Verastem 607.94 Mn 410.11 Mn 15.90 Mn 29.77%

Historic Data

Download Data
DateValue
Mar 31, 2026 29.77%
Dec 31, 2025 52.95%
Sep 30, 2025 -311.06%
Jun 30, 2025 -214.12%
Mar 31, 2025 -53.86%
Dec 31, 2024 -135.86%
Sep 30, 2024 -20.10%
Jun 30, 2024 66.00%
Mar 31, 2024 -115.50%
Dec 31, 2023 -62.50%
Sep 30, 2023 -10.87%
Jun 30, 2023 -10.61%
Mar 31, 2023 7.36%
Dec 31, 2022 -2.07%
Sep 30, 2022 21.01%
Jun 30, 2022 -29.88%
Mar 31, 2022 -12.85%
Dec 31, 2021 16.94%
Sep 30, 2021 -273.44%
Jun 30, 2021 26.54%